Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months

3 weeks ago 2

• Healthcare

jetcityimage/iStock Editorial via Getty Images

Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an early-stage trial, according to data published on Friday ahead of a healthcare conference next week.

Citing an abstract posted ahead of

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months